Syntara the science explained, page-159

We want to emphasise that although SNT-5505 will be administered to patients on top ofruxolitinib in this trial, any benefit experienced by patients is almost certainly to be relatedto SNT-5505 rather than ruxolitinib. This is because, as seen in Figure 4 below, patientswho benefit from ruxolitinib typically do so within the first 12 weeks (whether its symptomscores or spleen reduction). Therefore, because patients in the trial will have already beenon a stable dose of ruxolitinib for >12 weeks before receiving SNT-5505, there is unlikely tobe any further incremental efficacy benefit derived from ruxolitinib.

Very important